Extended Use of The Spanner® Temporary Prostatic Stent in Catheter-Dependent Men with Comorbidities
Table 4
PVR, Qmax, IPSS, and QOL measured during Spanner use.
Characteristics
1st Spanner placement
1st month of Spanner use
2nd month of Spanner use
3rd month of Spanner use
Total
PVRi
Mean ± SD
65.6 ± 107.1
45.4 ± 43.4
46.7 ± 78.9
53.5 ± 66.4
53.3 ± 78.9
Median
35.0
30
27
36
31
Min-Max
0–856.8
0–176.0
0–547.1
0–537.0
0–856.8
n
101
88
84
82
355
Qmax (ml/sec)
Mean ± SD
11.9 ± 7.0
11.4 ± 7.1
11.8 ± 6.4
9.6 ± 5.4
11.2 ± 6.6
Median
10.0
10.1
11.6
8.2
10
Min-Max
1.0–34.0
1.6–38.4
0.9–33.2
0.8–27.0
0.8–38.4
n
93
84
73
73
323
IPSS
NAii
Mean ± SD
7.7 ± 6.8
7.6 ± 6.2
7.1 ± 6.2
7.5 ± 6.4
Median
5
6
5
5
Min-Max
0–35
0–29
0–29
0–35
n
89
82
82
253
QOL
NAii
Mean ± SD
2.0 ± 1.6
2.0 ± 1.5
2.0 ± 1.7
2.0 ± 1.6
Median
2
2
1
2
Min-Max
0–6
0–6
0–6
0–6
n
89
82
82
253
Standard urological measures as assessed at each study visit for all enrolled patients. (i) Patients with a PVR > 350 ml were removed from the study. Patients with a PVR > 250 ml and <350 ml were scheduled for a follow-up visit within one week to monitor PVR. (ii) Patients were incapable of voluntary voiding at enrollment so the IPSS, a questionnaire assessing symptoms occurring during voiding, was not administered.
